CAQK side effects — no human has been dosed: what the mouse, rat and pig studies show and what they cannot

CAQK Side Effects: What the Evidence Actually Shows

REVIEWED BY

Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor

Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn

Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy

Citations verified against PubMed · Published: 2026-09-15 · Last updated: 2026-09-15

CAQK side effects have never been measured in a human being. Not in a trial, not in a case report, not in a registry entry: as of September 15, 2026, ClinicalTrials.gov lists no study of this four-amino-acid peptide, and the entire PubMed literature on the peptide is mouse, rat, pig and cell-culture work, plus binding tests on injured human brain tissue. That is the whole safety file, and this page is built around that fact rather than around the borrowed lists that fill the gap elsewhere. What exists instead is unusually interesting for a research-market peptide — a decade of animal studies, a 2024 systematic review, and a 2025 paper in which the discoverers finally tested the peptide on its own — and every claim you will read elsewhere about CAQK’s side effects traces back to one of those animal experiments, or to nothing.

Quick Answer: What the CAQK Side-Effect Data Actually Shows

There is no published human safety data for CAQK — no human has been dosed in any reported study. A 2024 systematic review found 16 animal studies, almost all using CAQK as a delivery tag for another drug, and concluded that “no studies directly evaluated the effects of CAQK alone” (PMID 39456774). The first study to do so, in 2025, gave the peptide intravenously to mice with brain injury and reported improved outcomes “with no overt toxicity” (PMID 41034343). A 2026 rat study used 2.5 mg/kg intravenously for seven days after spinal cord injury and reported motor recovery, not adverse events (PMID 42378652). Every study that reports a route delivered CAQK through the bloodstream, and the treatment studies dosed within hours of an acute injury; imaging and delivery studies also dosed days to weeks after a lesion. Nothing exists on subcutaneous use, on uninjured subjects, on treatment of chronic injury, or on people — which is the population buying it.

★The Documented Experience: Zero Monitored Humans

On our larazotide and retatrutide pages, this box summarizes what hundreds or thousands of monitored trial participants went through. For CAQK the honest version is short: no human being has received CAQK under conditions where a side effect could have been recorded. The closest documented experience belongs to mice and pigs with laboratory-induced brain injury and rats with a cervical spinal cord contusion — animals dosed through the bloodstream within an hour of injury in the rat work and “shortly after” in the mouse and pig work, then assessed for the injury, not for the drug.

People appear to be buying CAQK anyway; a September 2026 Reddit post asking how to calculate a dose suggests as much. Their experiences, whatever they are, have never been collected. When we searched, we found questions and no answers — not one first-hand report of having taken it.

Source: PMIDs 41034343, 42378652, 39456774. When we publish an individual account here, it will be a real person, named with permission. We don’t write fiction into this slot.

Research peptide vial

Looking for Lab-Tested Peptides?

Neither vendor we review stocks CAQK (checked September 15, 2026). Our top-rated vendor publishes batch COAs and third-party testing on every compound it does carry — get up to 30% off your first order.

Shop Amino Club →

Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.

In This Guide

What Is CAQK?

CAQK is a tetrapeptide — four amino acids, cysteine-alanine-glutamine-lysine — identified in 2016 by in vivo phage display screening in mice with acute brain injury — a method in which libraries of phage carrying random short peptides are injected and the sequences that accumulate in the tissue of interest are recovered — and named for its letters (PMID 27351915). The discovery paper showed that CAQK binds selectively to injured mouse brain and to injured human brain tissue, that systemically injected CAQK homes to sites of brain injury in mouse models, and that coupling other molecules to it — from drug-sized compounds to nanoparticles carrying gene-silencing RNA — increased their accumulation in the injured tissue.

That origin matters for a side-effects page. CAQK was not discovered as a treatment. It was discovered as a targeting peptide: a molecular address label that finds the extracellular matrix that injured brain and spinal cord lay down, so that something else attached to it can be delivered there. For nine years nearly every study used it that way. Only in 2025 did its discoverers publish a test of CAQK by itself as a therapeutic (PMID 41034343), and only in 2026 did a different group repeat that in a spinal cord model (PMID 42378652). Research-market vials are now sold as a “brain injury” or “neuroprotective” peptide to an audience that, judging by the one substantive thread we found, is years past any acute injury. Our peptides for brain health page covers the wider category; this page covers what is and is not known about harm.

How It Works — an Address, Not a Drug

When the central nervous system is injured, reactive astrocytes deposit a dense extracellular matrix rich in chondroitin sulfate proteoglycans. CAQK binds to a proteoglycan complex that is upregulated in injured brain (PMID 27351915); a 2022 study found it associating with the fibrous matrix near reactive astrocytes at demyelinating lesions, with some binding to tenascin-C (PMID 36072569). In healthy tissue that matrix is scarce, so the peptide has little to bind — the 2026 rat imaging study found no significant signal in uninjured spinal cord regions or in control animals (PMID 41247331).

The 2025 therapeutic paper proposes that binding is also the mechanism of benefit: CAQK treatment reduced injury size in mice, with reduced upregulation of the matrix glycoprotein complex it binds, less apoptosis, and lower expression of inflammatory markers in the injured area — a picture the authors read as dampened neuroinflammation and less secondary injury (PMID 41034343). Whether a four-residue peptide sitting on scar matrix does that by blocking something, by displacing something, or by some other route is not settled in the abstracts.

KEY TAKEAWAY

CAQK’s mechanism is binding to injury-specific matrix, which is why it has almost nowhere to act in a body without an acute CNS injury. That cuts both ways for a buyer: it is a plausible reason to expect little effect of any kind in an uninjured person, and it is also the reason no animal study has ever looked for one. “Nowhere to act” is a hypothesis, not a safety finding.

The Entire Evidence Base: Animal Studies, Zero Humans

PubMed returned 29 hits for CAQK on September 15, 2026, none of them human. A 2024 systematic review, searching multiple databases with PRISMA methods, found 16 studies meeting its criteria, with mice and rats the predominant models; all but one used CAQK to deliver a therapeutic agent rather than as the agent itself, most used intravenous administration, and the reviewers noted that heterogeneity in methods and the absence of direct comparisons between CAQK and its cargo limited what could be concluded (PMID 39456774). The studies most relevant to safety:

Study Subjects What CAQK did in it Safety content
Discovery, 2016 (PMID 27351915) Mice with acute brain injury; human brain tissue ex vivo Homed to injury after systemic injection; carried nanoparticles and siRNA None reported in abstract
TBI nanoparticles, 2019 (PMID 31213815) Mice with TBI Targeting tag on 30 nm nanoparticles carrying a neuroprotective peptide Nanoparticle reduced the cargo’s cytotoxicity in cells; nothing on CAQK itself
Demyelination homing, 2022 (PMID 36072569) Three mouse models of demyelination Fluorescent CAQK homed to lesions; absent from healthy tissue None reported in abstract
MS-model delivery, 2023 (PMID 38107502) Mice, lysolecithin demyelination Coated silicon nanoparticles carrying methylprednisolone, single 0.24 mg dose None reported in abstract
Systematic review, 2024 (PMID 39456774) 16 studies, mice and rats Carrier in all but one study “No studies directly evaluated the effects of CAQK alone”
CAQK alone in TBI, 2025 (PMID 41034343) Mice (efficacy) and pigs (accumulation), moderate or severe TBI IV shortly after injury; smaller injury, less apoptosis and inflammation, improved function “No overt toxicity”
Pharmacokinetics, 2025 (PMID 40577388) Mice with TBI Free peptide vs PEG conjugates; conjugation extended blood half-life 90-fold Longer retention of one conjugate type in liver, kidney and spleen
SCI homing, 2026 (PMID 41247331) 24 rats, cervical hemicontusion Fluorescent CAQK at 0.5, 1.0 or 2.5 mg/kg IV; dose-dependent signal, peak within 24 h, persisting to 7 days at the high dose None reported in abstract
SCI treatment, 2026 (PMID 42378652) 12 female rats, cervical hemicontusion 2.5 mg/kg IV daily for 7 days from 1 hour post-injury; forelimb score 7 vs 3 at week 8 None reported in abstract

Read the right-hand column top to bottom. Across a decade of work, the sum of published safety observations on CAQK is three words from one mouse study and a biodistribution note about a polymer conjugate. Nobody has been negligent — these were targeting and efficacy experiments, and toxicology was not their question. But it means the safety question has never been asked in the literature, let alone answered.

The Side-Effect Dataset That Doesn’t Exist

A side-effect profile is built from a specific kind of study: dosed subjects observed for events, against a comparator, with the events counted. For CAQK, no such study exists in any species. No abstract in the literature reports dose-escalation toxicology, repeat dosing in uninjured animals, organ histology after chronic dosing, or an immunogenicity assessment — and, the point of this page, there is no human exposure of any kind. ClinicalTrials.gov returned zero studies for the term on September 15, 2026, and none of the 29 PubMed records for it carries a clinical-trial publication type.

This is a different situation from the other no-data peptides we cover. AHK-Cu has a cosmetic track record to lean on; dihexa has years of rodent behavioral work; 5-Amino-1MQ has a small-molecule literature. CAQK has ten years of animal data, all of it about whether the peptide reaches the injury and whether the cargo works once it gets there. It is possible to know a great deal about a molecule’s targeting and nothing about its tolerability, and that is precisely CAQK’s position.

PERSONAL OBSERVATION — PI EDITORIAL

Working through all 29 PubMed results for this page, the thing that struck us was how consistently the word “CAQK” appears as a modifier — CAQK-coated, CAQK-conjugated, CAQK-modified, CAQK-decorated. The peptide is the postage on a parcel. The one Reddit explainer we found introduces it alongside Semax, Selank and dihexa, as if it were the next nootropic — the parcel, not the postage. Nothing in the literature says a bare tetrapeptide in a vial does what a methylprednisolone nanoparticle wearing that tetrapeptide did in a mouse. The 2025 paper is the first to make a case for the bare peptide, and it is one paper, in mice, with one line about toxicity.

What the Animal Studies Did Record About Safety

Two observations exist, and they should be quoted rather than inflated. The 2025 therapeutic study reports that CAQK treatment improved functional deficit in TBI mice “with no overt toxicity” (PMID 41034343). “No overt toxicity” in a mouse efficacy study means the animals did not visibly sicken or die from the treatment over the study period — it is a floor, not a toxicology report, and the abstract does not describe what was monitored, for how long, or at what dose.

The second observation concerns not CAQK but what happens when it is attached to a polymer. In the pharmacokinetics study, conjugating CAQK to polyethylene glycol extended its blood half-life about 90-fold; one of the two linker chemistries tested produced longer retention in the liver, kidney and spleen than the other (PMID 40577388). That is a biodistribution finding about an engineered conjugate, and it tells you two things about the free peptide by contrast: unconjugated CAQK clears fast, and the versions built to overcome that clearance are not the version in a research vial. Everything else in the safety column of the table above is blank.

The Pharmacokinetics Problem the Vial Version Inherits

The 2025 pharmacokinetics paper states the problem plainly: “like many peptides, CAQK has poor pharmacokinetics, with rapid systemic clearance limiting its therapeutic potential” (PMID 40577388). The authors’ solution was to build long-circulating PEG conjugates, which raised injured-brain accumulation and even allowed the peptide to be given 24 hours before an injury as a prophylactic, with 4.5% of the injected dose per gram of tissue found in the injured brain.

The research-market product is the unconjugated tetrapeptide — the form the researchers were working to get away from. For a side-effects page that has a specific implication: fast clearance limits exposure, which is a plausible reason to expect fewer systemic effects, but it also means the animal efficacy results were obtained by dosing soon after injury — within an hour in the rat study — when there was still a circulating window to exploit, and repeating daily. A vial cannot borrow the conjugate’s persistence, and it cannot borrow the free peptide’s safety record, because the free peptide does not have one.

Every Study Used a Vein: The Subcutaneous Zero-Data Zone

In every animal study on this page that states a route, CAQK reached the animal through the bloodstream — tail-vein injection in the rat studies (PMID 41247331), intravenous administration in the TBI mice and pigs (PMID 41034343), and intravenous delivery of the nanoparticle formulations (PMID 38107502). The systematic review confirms intravenous administration as the norm across its 16 studies (PMID 39456774).

Research peptides in this market are generally reconstituted for subcutaneous injection, and there is no study of subcutaneous CAQK in any species: no absorption data, no bioavailability, no local-reaction observation, nothing. Given rapid clearance from blood, whether a subcutaneous depot delivers any meaningful amount to the circulation — let alone to the brain — is an open question no one has published on. Injection-site reactions, a common side effect of injected peptides, have never been assessed for this one because it has never been injected that way in a study.

Acute Injury Only: Why Timing Is the Whole Design

CAQK binds matrix that appears after injury, so every study dosed soon after one: the 2026 spinal cord treatment study began intravenous dosing one hour post-injury and continued for seven days (PMID 42378652); the 2025 TBI study administered it “shortly after moderate or severe TBI” (PMID 41034343); the imaging study saw peak accumulation within 24 hours of injection in injured rats (PMID 41247331). The exceptions run in both directions: a conjugate given prophylactically 24 hours before injury (PMID 40577388), and imaging or delivery studies that dosed five days after a demyelinating lesion (PMID 38107502) or after six weeks of cuprizone-induced demyelination (PMID 36072569) — binding studies, not treatment studies.

The people asking about CAQK online are not in an emergency department. The one substantive Reddit post we found came from someone three years past emergency neurosurgery for a brain abscess, asking whether the peptide could help in the chronic phase and noting that most of what they had read pointed to acute injury (thread). That reading is correct. Whether the injury-associated matrix that CAQK binds persists in a chronic lesion (PMID 36072569) has not been studied as a treatment question in any model, and certainly not in a person. What the 2022 work does show is CAQK binding fibrous matrix around reactive astrocytes at established lesions in mice, including after six weeks of cuprizone-induced demyelination.

Why “No Reported Side Effects” Isn’t “No Side Effects”

We searched Reddit on September 15, 2026 for CAQK and found five relevant posts in total. Two are the chronic-injury question above, cross-posted to two subreddits; the one copy that drew replies got two — someone asking where to buy it, and the original poster answering that they had not found a source (thread). Two are a cross-posted September 2026 question about calculating a dose, with no substantive reply (thread). One is an explainer post summarizing the research (thread). Not one person, anywhere we looked, describes having taken CAQK.

So when anyone says CAQK has “no reported side effects,” the statement is literally true and completely uninformative: nothing has been reported because almost nobody has reported anything at all. Compare our retatrutide side-effects page, which draws on trials in hundreds of people and a dozen active Reddit threads. The difference between that page and this one is not that CAQK is safer. It is that CAQK has never been looked at.

Doses: What the Animal Studies Actually Used

For reference only — these are the exposures the published studies administered to animals, and there is no human dose of CAQK because there has never been a human study. The rat imaging study compared 0.5, 1.0 and 2.5 mg/kg intravenously and found signal at the injury dose-dependent, with the high dose persisting to seven days (PMID 41247331). The rat treatment study used 2.5 mg/kg intravenously, daily, for seven days (PMID 42378652). The mouse MS-model study gave a single 0.24 mg dose — of the drug-loaded nanoparticle, not of free peptide (PMID 38107502). The 2025 TBI abstract does not state its dose.

None of that converts to a person. Milligram-per-kilogram scaling between a rat and a human is not a matter of multiplying by body weight, the route was intravenous in every case, and the animals were acutely injured. If you are handling a research vial, our peptide calculator does arithmetic on an amount you enter; it does not, and for this compound cannot, propose one.

DID YOU KNOW

The “C” in CAQK is not incidental. As a matter of general peptide chemistry, cysteine carries a thiol group, and that thiol is a standard handle for attaching a peptide to nanoparticles and polymers — the 2025 pharmacokinetics study built one of its two conjugate types through exactly that maleimide-thiol reaction, the other through DBCO-azide chemistry, and the two differed in how long they lingered in off-target organs (PMID 40577388). CAQK was selected for what it binds, then used almost exclusively as something to attach other molecules to. A vial of the free peptide is the one form of it the literature was never really about.

Stacking CAQK: The Cargo Question

Every “combination” of CAQK in the literature is a cargo: a neuroprotective peptide inside nanoparticles (PMID 31213815), methylprednisolone in porous silicon (PMID 38107502), silencing RNA (PMID 27351915). In each case the therapeutic effect was attributed to the cargo, with CAQK as the address — though the 2024 review notes that no study directly compared CAQK against its cargo, so the split is assumed rather than measured (PMID 39456774). The MS-model study makes the logic explicit: the same dose of free methylprednisolone did nothing measurable, while the CAQK-targeted nanoparticle reduced glial activation, because the targeting concentrated the drug where it was needed.

That is the opposite of how research-market “stacks” work, where CAQK is mixed with other free peptides in separate vials and nothing is chemically attached to anything. No study has tested CAQK alongside any other free peptide — not Semax, not Selank, not dihexa, not pinealon — and there is no mechanism by which an unattached targeting peptide would escort a separate molecule anywhere. A stack containing CAQK has, on current evidence, CAQK’s unknown side effects plus each other component’s.

Where the Lab Data Stops: The Research-Vial Reality

Everything above describes CAQK made in a laboratory, verified by the researchers who made it, and given intravenously to injured animals. A research vial labeled CAQK is sold for non-human research use, with no regulatory review of what is in it, and with an implied use — subcutaneous injection into an uninjured or long-ago-injured person — that no study has examined. The gap between those two products is the entire content of this page.

PERSONAL OBSERVATION — PI EDITORIAL

Neither of the two vendors we review listed CAQK when we checked on September 15, 2026, so we have no batch certificates to compare — which is itself a data point about how far out on the research market this compound sits. We have not audited listings elsewhere, and this page makes no claim about them. If you take one thing from this page, make it this: the certificate of analysis is the only document that connects a vial to the molecule in the papers, and for a four-residue peptide with a reactive cysteine, identity and purity are not formalities.

PRACTICAL NOTES — WHAT THE STUDIES DID, NOT INSTRUCTIONS

  • Every published animal study that states a route gave CAQK through the bloodstream; the treatment studies dosed within an hour of injury in rats and “shortly after” in mice and pigs, and no study describes subcutaneous use or an uninjured subject
  • Cysteine is, in general peptide chemistry, a reactive residue — it is the handle the researchers used for conjugation — so the certificate should identify the molecule by mass spectrometry, not just by name
  • Ask whether the certificate reports purity by HPLC and lists related impurities separately — our guide to reading a COA covers what those line items mean
  • A brain or spinal cord injury is managed by a neurologist or neurosurgeon; nothing on this page bears on that care

Sourcing and Verification

As of September 15, 2026, neither Amino Club nor Mile High Compounds lists CAQK. Where it appears on the research market, the standard is the one we apply everywhere: a certificate of analysis for the specific lot, identity confirmed by mass spectrometry, purity by HPLC, from a named third-party laboratory — see our lab-testing guide and our framework for spotting a fake peptide website. A listing that cannot show the molecule’s mass is showing you a name on a label. Everything sold in this market is labeled for non-human research use, and for CAQK that label is not a formality: non-human research is the only research that has ever been done.

US Regulatory Status

CAQK is not an approved drug and has no compounding pathway. It is, as of late 2025, a declared drug candidate: Aivocode, which an October 2025 news release describes as the company leading the 2025 mouse-and-pig study alongside IQAC-CSIC and UC Davis, said it “plans to soon seek authorization from the U.S. Food and Drug Administration (FDA) to begin Phase I clinical trials in humans,” with no date set (EurekAlert, October 7, 2025). As of September 15, 2026, ClinicalTrials.gov holds no record under the term, so no human study has started. Until one does, CAQK exists in two places: academic laboratories, where it remains an active research tool for drug delivery in brain and spinal cord injury, and the research-chemical market, where vials are sold with no regulatory review. Like ENDO-205, it is a compound whose first human safety data will arrive as a Phase 1 registry entry — and this page will change the week it does.

Other research-market compounds with no human safety data, given the same honest treatment: AHK-Cu, dihexa, PE-22-28, humanin, FOXO4-DRI, 5-Amino-1MQ and SLU-PP-915. For the opposite end of the evidence scale on a gut peptide sold to a similar audience, see larazotide, which has five human trials.

Frequently Asked Questions

What are the side effects of CAQK?

Unknown. No human has taken CAQK in any published study, and no clinical trial exists. The animal literature is about targeting and efficacy, not tolerability; its entire safety content is one 2025 mouse study reporting “no overt toxicity” and a biodistribution note about a polymer conjugate. Any list of CAQK side effects you see elsewhere is not from the research.

Is CAQK safe?

No published data answers that in either direction. Nothing documents harm; nothing demonstrates safety. The peptide has been given intravenously to injured mice, rats and pigs in efficacy experiments, never to a person, and never in a study designed to measure adverse effects.

Is CAQK safe to inject subcutaneously?

There is no study of subcutaneous CAQK in any species. Every published study used intravenous administration. Absorption, bioavailability and injection-site reactions after subcutaneous use have never been measured, and the peptide is known to clear rapidly from blood even when given by vein.

Does CAQK work for old brain injuries?

No study has tested it in chronic injury. Every therapeutic study dosed within hours of an acute injury, because CAQK binds matrix laid down by the injury response. Whether that matrix persists in a years-old lesion in a form the peptide can bind has not been studied as a treatment question in any animal, and not at all in people.

Is CAQK a neuroprotective peptide?

It was discovered as a targeting peptide that homes to injured brain and spinal cord, and for nine years it was used to deliver other drugs. A 2025 mouse study and a 2026 rat study reported that CAQK alone improved outcomes after acute injury; those are the first and only such results, in animals, and no human data exists.

Can you buy CAQK?

Some research-chemical sites list it for non-human research use; neither vendor we review stocked it as of September 15, 2026. It is not available through any regulated channel, has no approved or investigational human use, and a certificate confirming identity by mass spectrometry is the only way to know a vial contains the molecule in the papers.

Glossary of Terms

  • CAQK: the tetrapeptide cysteine-alanine-glutamine-lysine (C-A-Q-K), identified in 2016 as a peptide that homes to acute central nervous system injury. Two of the cited abstracts spell the residues out as “cysteine-alanine-lysine glutamine”; the letters, and the other papers, give the order used here.
  • Homing (targeting) peptide: a short sequence that binds a tissue-specific target and is used to carry attached drugs or particles there; a delivery address rather than a therapeutic.
  • In vivo phage display: the screening method that found CAQK — injecting libraries of peptide-displaying viruses into a living animal and recovering the sequences that accumulate in the tissue of interest.
  • Chondroitin sulfate proteoglycans (CSPGs): extracellular-matrix molecules deposited by reactive astrocytes after CNS injury; the target class CAQK binds.
  • Hemicontusion: the standardized one-sided spinal cord injury used in the 2026 rat studies; the mouse and pig brain-injury models are described in the papers as moderate or severe TBI.
  • IBB scale: the Irvine, Beatties and Bresnahan forelimb recovery scale (0–9) used to score motor recovery in the 2026 rat study.
  • PEG conjugate: the peptide attached to polyethylene glycol to slow its clearance — the long-circulating form studied in 2025, and not what is sold in a research vial.
  • “No overt toxicity”: an efficacy-study observation that treated animals showed no visible illness or death attributable to treatment; not a toxicology assessment.

References